10/19/2005 5:12:11 PM
TransForm Pharmaceuticals, Inc. today announced it has initiated its first Phase II clinical trial with its lead product candidate, TPI-926, for treatment in patients suffering from a disease of the central nervous system (CNS). The compound is a novel and proprietary reformulation of an existing marketed product and is expected to have important clinical advantages over current treatment. There are an estimated one million CNS patients that could benefit from this reformulated product which is expected to reach the market in 2007.
comments powered by